Roche Holding AG (RHHBY.PK), Tuesday announced the primary results from the TSIX Study Program, which evaluated the performance of its new sixth-generation high-sensitivity Elecsys Troponin T test for diagnosing heart attacks.
The results showed that the test was able to detect even the slightest elevations in troponin levels, a critical biomarker for heart attack, enabling patients to receive life-saving care at the earliest.
It also identified whether patients had acute myocardial infarction or not with huge precision, helping clinicians to provide faster and reliable diagnosis in emergencies.
Currently, Roche's stock is moving up 3.33 percent, to $40.91 on the OTC Markets.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.